These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 11810078

  • 1. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.
    Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC, Ortho Evra/Evra 001 Study Group.
    Am J Obstet Gynecol; 2002 Jan; 186(1):15-20. PubMed ID: 11810078
    [Abstract] [Full Text] [Related]

  • 2. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
    Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW.
    Fertil Steril; 2003 Jul; 80(1):34-42. PubMed ID: 12849799
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.
    Goa KL, Warner GT, Easthope SE.
    Treat Endocrinol; 2003 Jul; 2(3):191-206. PubMed ID: 15966567
    [Abstract] [Full Text] [Related]

  • 5. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit.
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a transdermal contraceptive system.
    Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW, ORTHO EVRA/EVRA 002 Study Group.
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):799-805. PubMed ID: 11704172
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
    Abrams LS, Skee DM, Natarajan J, Wong FA, Leese PT, Creasy GW, Shangold MM.
    J Clin Pharmacol; 2001 Dec; 41(12):1301-9. PubMed ID: 11762557
    [Abstract] [Full Text] [Related]

  • 8. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol.
    Bjarnadóttir RI, Tuppurainen M, Killick SR.
    Am J Obstet Gynecol; 2002 Mar; 186(3):389-95. PubMed ID: 11904596
    [Abstract] [Full Text] [Related]

  • 9. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M, Haukkamaa M, Lähteenmäki P.
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).
    Archer DF, Maheux R, DelConte A, O'Brien FB.
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):39-44. PubMed ID: 10561674
    [Abstract] [Full Text] [Related]

  • 11. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN, Burkman R, Fisher AC, LaGuardia KD.
    Int J Fertil Womens Med; 2003 Nov; 48(4):163-72. PubMed ID: 13677549
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
    Abrams LS, Skee DM, Wong FA, Anderson NJ, Leese PT.
    J Clin Pharmacol; 2001 Nov; 41(11):1232-7. PubMed ID: 11697756
    [Abstract] [Full Text] [Related]

  • 13. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
    Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, Fisher AC, Creasy GW.
    Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic overview of Ortho Evra/Evra.
    Abrams LS, Skee D, Natarajan J, Wong FA.
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
    [Abstract] [Full Text] [Related]

  • 15. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D, Skřivánek A, Serrani M, Lanius V, Merz M.
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [Abstract] [Full Text] [Related]

  • 16. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL, Reinecke I, Bangerter K, Merz M.
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [Abstract] [Full Text] [Related]

  • 17. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol.
    Reisman H, Martin D, Gast MJ.
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):45-52. PubMed ID: 10561675
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.
    Roumen FJ, Apter D, Mulders TM, Dieben TO.
    Hum Reprod; 2001 Mar; 16(3):469-75. PubMed ID: 11228213
    [Abstract] [Full Text] [Related]

  • 19. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M, Kroll R, Lynen R, Bangerter K.
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [Abstract] [Full Text] [Related]

  • 20. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.